An economic evaluation of universal pertussis vaccination in Italy.
An economic evaluation was performed of universal acellular pertussis vaccination in Italy, where until recently the overall coverage of pertussis vaccination was estimated at 50%. Over the last two years coverage seems to have increased rapidly. By means of a mathematical simulation model, the consequences of pertussis vaccination in terms of both health effects and economic costs were calculated for a single birth cohort followed for 6 years. Incremental analyses were performed for each additional 10% increase in coverage from 50-90%. The results indicate that a 50% coverage rate of pertussis vaccination in Italy was not optimal on the basis of cost-effectiveness and cost-benefit considerations. Additional increases in coverage were found to yield extra health gains at modest net costs or even potential net savings to the health care sector. For example, an increase in coverage to 90% would yield direct net savings of US$42 per extra vaccinee in comparison to a situation of 50% coverage. The total net savings for this strategy would be well over US$100 per additional vaccinee. In the sensitivity analysis, the positive relationship between incremental coverage and incremental efficiency remained unchanged.
Center for the Evaluation of Vaccination, Epidemiology and Community Medicine, University of Antwerp, Belgium. pbeutels@uia.ua.ac.be
P
P
Beutels
P
P
Bonanni
G
G
Tormans
F
F
Canale
P C
PC
Crovari
D003362:Cost-Benefit Analysis; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000191:economics; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006801:Humans; D007558:Italy; D010567:Pertussis Vaccine / Q000191:economics*; D017778:Vaccines, Combined / Q000191:economics; D014917:Whooping Cough / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D010567:Pertussis Vaccine; D017778:Vaccines, Combined